世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
膣真菌症治療薬 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030Drugs for Vaginal Fungal Infections - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 膣真菌症治療薬の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。 世界の医薬品市場は2022年に1,475億米ドル... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー膣真菌症治療薬の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。世界の医薬品市場は2022年に1,475億米ドルで、今後6年間のCAGRは5％で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。 レポートの範囲 本レポートは、膣真菌症治療薬の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングを中心に包括的に紹介することを目的としています。 膣真菌症治療薬の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。量的および質的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、膣真菌感染症治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 ファイザー ボシュ・ヘルス・カンパニーズ アンル・ファーマシューティカルズ ヒクマ・ファーマシューティカルズ ルピン・リミテッド マイコビア・ファーマシューティカルズ・インク グレンマーク社 ユニーク・ファーマシューティカルズ ペプトニック・メディカルAB オーロビンド・ファーマ・リミテッド ドクター・レディーズ・ラボラトリーズ SCYNEXIS社 バシレアファーマスーティカ アステラス製薬 グルポ・フェレール・インターナシオナル S.A. パックジェン・ライフサイエンス・コーポレーション ノバディグム・セラピューティクス社 シダラ・セラピューティクス社 Amplyx Pharmaceuticals Inc. タイプ別セグメント フルコナゾール ナイスタチン フルシトシン クロトリマゾール その他 用途別セグメント 病院 クリニック その他 地域別 北米 アメリカ カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章： レポートのスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：膣真菌症治療薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章：読者が異なる川下市場におけるブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの市場規模と発展の可能性をカバーする、アプリケーション別の様々な市場セグメントの分析を提供します。 第5章：地域レベルでの膣真菌症治療薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章：膣真菌症治療薬の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介します。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Drugs for Vaginal Fungal Infections Product Introduction 1.2 Global Drugs for Vaginal Fungal Infections Market Size Forecast 1.3 Drugs for Vaginal Fungal Infections Market Trends & Drivers 1.3.1 Drugs for Vaginal Fungal Infections Industry Trends 1.3.2 Drugs for Vaginal Fungal Infections Market Drivers & Opportunity 1.3.3 Drugs for Vaginal Fungal Infections Market Challenges 1.3.4 Drugs for Vaginal Fungal Infections Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Drugs for Vaginal Fungal Infections Players Revenue Ranking (2023) 2.2 Global Drugs for Vaginal Fungal Infections Revenue by Company (2019-2024) 2.3 Key Companies Drugs for Vaginal Fungal Infections Manufacturing Base Distribution and Headquarters 2.4 Key Companies Drugs for Vaginal Fungal Infections Product Offered 2.5 Key Companies Time to Begin Mass Production of Drugs for Vaginal Fungal Infections 2.6 Drugs for Vaginal Fungal Infections Market Competitive Analysis 2.6.1 Drugs for Vaginal Fungal Infections Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Drugs for Vaginal Fungal Infections Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vaginal Fungal Infections as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Fluconazole 3.1.2 Nystatin 3.1.3 Flucytosine 3.1.4 Clotrimazole 3.1.5 Others 3.2 Global Drugs for Vaginal Fungal Infections Sales Value by Type 3.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (2019-2030) 3.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Drugs for Vaginal Fungal Infections Sales Value by Application 4.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (2019-2030) 4.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region 5.1.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2019-2024) 5.1.3 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2025-2030) 5.1.4 Global Drugs for Vaginal Fungal Infections Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.2.2 North America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.3.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.4.2 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.5.2 South America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.6.2 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value 6.3 United States 6.3.1 United States Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.3.2 United States Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.4.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.5.2 China Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.5.3 China Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.6.2 Japan Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.7.2 South Korea Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.8.2 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.9.2 India Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.9.3 India Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Pfizer Inc. 7.1.1 Pfizer Inc. Profile 7.1.2 Pfizer Inc. Main Business 7.1.3 Pfizer Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.1.4 Pfizer Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.1.5 Pfizer Inc. Recent Developments 7.2 Bausch Health Companies Inc 7.2.1 Bausch Health Companies Inc Profile 7.2.2 Bausch Health Companies Inc Main Business 7.2.3 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.2.4 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.2.5 Bausch Health Companies Inc Recent Developments 7.3 ANl Pharmaceuticals, Inc 7.3.1 ANl Pharmaceuticals, Inc Profile 7.3.2 ANl Pharmaceuticals, Inc Main Business 7.3.3 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.3.4 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.3.5 Hikma Pharmaceuticals Plc Recent Developments 7.4 Hikma Pharmaceuticals Plc 7.4.1 Hikma Pharmaceuticals Plc Profile 7.4.2 Hikma Pharmaceuticals Plc Main Business 7.4.3 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.4.4 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.4.5 Hikma Pharmaceuticals Plc Recent Developments 7.5 Lupin Limited 7.5.1 Lupin Limited Profile 7.5.2 Lupin Limited Main Business 7.5.3 Lupin Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.5.4 Lupin Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.5.5 Lupin Limited Recent Developments 7.6 Mycovia Pharmaceuticals, Inc. 7.6.1 Mycovia Pharmaceuticals, Inc. Profile 7.6.2 Mycovia Pharmaceuticals, Inc. Main Business 7.6.3 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.6.4 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.6.5 Mycovia Pharmaceuticals, Inc. Recent Developments 7.7 Glenmark Pharmaceuticals Limited 7.7.1 Glenmark Pharmaceuticals Limited Profile 7.7.2 Glenmark Pharmaceuticals Limited Main Business 7.7.3 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.7.4 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.7.5 Glenmark Pharmaceuticals Limited Recent Developments 7.8 Unique Pharmaceuticals 7.8.1 Unique Pharmaceuticals Profile 7.8.2 Unique Pharmaceuticals Main Business 7.8.3 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.8.4 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.8.5 Unique Pharmaceuticals Recent Developments 7.9 PEPTONIC Medical AB 7.9.1 PEPTONIC Medical AB Profile 7.9.2 PEPTONIC Medical AB Main Business 7.9.3 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.9.4 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.9.5 PEPTONIC Medical AB Recent Developments 7.10 Aurobindo Pharma Limited 7.10.1 Aurobindo Pharma Limited Profile 7.10.2 Aurobindo Pharma Limited Main Business 7.10.3 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.10.4 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.10.5 Aurobindo Pharma Limited Recent Developments 7.11 Dr. Reddy's Laboratories 7.11.1 Dr. Reddy's Laboratories Profile 7.11.2 Dr. Reddy's Laboratories Main Business 7.11.3 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.11.4 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.11.5 Dr. Reddy's Laboratories Recent Developments 7.12 SCYNEXIS,Inc. 7.12.1 SCYNEXIS,Inc. Profile 7.12.2 SCYNEXIS,Inc. Main Business 7.12.3 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.12.4 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.12.5 SCYNEXIS,Inc. Recent Developments 7.13 Basilea Pharmaceutica Ltd. 7.13.1 Basilea Pharmaceutica Ltd. Profile 7.13.2 Basilea Pharmaceutica Ltd. Main Business 7.13.3 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.13.4 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.13.5 Basilea Pharmaceutica Ltd. Recent Developments 7.14 Astellas Pharma lnc. 7.14.1 Astellas Pharma lnc. Profile 7.14.2 Astellas Pharma lnc. Main Business 7.14.3 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.14.4 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.14.5 Astellas Pharma lnc. Recent Developments 7.15 Grupo Ferrer Internacional,S.A. 7.15.1 Grupo Ferrer Internacional,S.A. Profile 7.15.2 Grupo Ferrer Internacional,S.A. Main Business 7.15.3 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.15.4 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.15.5 Grupo Ferrer Internacional,S.A. Recent Developments 7.16 Pacgen Life Science Corporation 7.16.1 Pacgen Life Science Corporation Profile 7.16.2 Pacgen Life Science Corporation Main Business 7.16.3 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.16.4 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.16.5 Pacgen Life Science Corporation Recent Developments 7.17 NovaDigm Therapeutics, Inc. 7.17.1 NovaDigm Therapeutics, Inc. Profile 7.17.2 NovaDigm Therapeutics, Inc. Main Business 7.17.3 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.17.4 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.17.5 NovaDigm Therapeutics, Inc. Recent Developments 7.18 Cidara Therapeutics, Inc. 7.18.1 Cidara Therapeutics, Inc. Profile 7.18.2 Cidara Therapeutics, Inc. Main Business 7.18.3 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.18.4 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.18.5 Cidara Therapeutics, Inc. Recent Developments 7.19 Amplyx Pharmaceuticals Inc. 7.19.1 Amplyx Pharmaceuticals Inc. Profile 7.19.2 Amplyx Pharmaceuticals Inc. Main Business 7.19.3 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.19.4 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.19.5 Amplyx Pharmaceuticals Inc. Recent Developments 8 Industry Chain Analysis 8.1 Drugs for Vaginal Fungal Infections Industrial Chain 8.2 Drugs for Vaginal Fungal Infections Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Drugs for Vaginal Fungal Infections Sales Model 8.5.2 Sales Channel 8.5.3 Drugs for Vaginal Fungal Infections Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Drugs for Vaginal Fungal Infections was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Drugs for Vaginal Fungal Infections Product Introduction 1.2 Global Drugs for Vaginal Fungal Infections Market Size Forecast 1.3 Drugs for Vaginal Fungal Infections Market Trends & Drivers 1.3.1 Drugs for Vaginal Fungal Infections Industry Trends 1.3.2 Drugs for Vaginal Fungal Infections Market Drivers & Opportunity 1.3.3 Drugs for Vaginal Fungal Infections Market Challenges 1.3.4 Drugs for Vaginal Fungal Infections Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Drugs for Vaginal Fungal Infections Players Revenue Ranking (2023) 2.2 Global Drugs for Vaginal Fungal Infections Revenue by Company (2019-2024) 2.3 Key Companies Drugs for Vaginal Fungal Infections Manufacturing Base Distribution and Headquarters 2.4 Key Companies Drugs for Vaginal Fungal Infections Product Offered 2.5 Key Companies Time to Begin Mass Production of Drugs for Vaginal Fungal Infections 2.6 Drugs for Vaginal Fungal Infections Market Competitive Analysis 2.6.1 Drugs for Vaginal Fungal Infections Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Drugs for Vaginal Fungal Infections Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vaginal Fungal Infections as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Fluconazole 3.1.2 Nystatin 3.1.3 Flucytosine 3.1.4 Clotrimazole 3.1.5 Others 3.2 Global Drugs for Vaginal Fungal Infections Sales Value by Type 3.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (2019-2030) 3.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Drugs for Vaginal Fungal Infections Sales Value by Application 4.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (2019-2030) 4.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region 5.1.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2019-2024) 5.1.3 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2025-2030) 5.1.4 Global Drugs for Vaginal Fungal Infections Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.2.2 North America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.3.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.4.2 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.5.2 South America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 5.6.2 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value 6.3 United States 6.3.1 United States Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.3.2 United States Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.4.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.5.2 China Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.5.3 China Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.6.2 Japan Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.7.2 South Korea Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.8.2 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Drugs for Vaginal Fungal Infections Sales Value, 2019-2030 6.9.2 India Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030 6.9.3 India Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Pfizer Inc. 7.1.1 Pfizer Inc. Profile 7.1.2 Pfizer Inc. Main Business 7.1.3 Pfizer Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.1.4 Pfizer Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.1.5 Pfizer Inc. Recent Developments 7.2 Bausch Health Companies Inc 7.2.1 Bausch Health Companies Inc Profile 7.2.2 Bausch Health Companies Inc Main Business 7.2.3 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.2.4 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.2.5 Bausch Health Companies Inc Recent Developments 7.3 ANl Pharmaceuticals, Inc 7.3.1 ANl Pharmaceuticals, Inc Profile 7.3.2 ANl Pharmaceuticals, Inc Main Business 7.3.3 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.3.4 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.3.5 Hikma Pharmaceuticals Plc Recent Developments 7.4 Hikma Pharmaceuticals Plc 7.4.1 Hikma Pharmaceuticals Plc Profile 7.4.2 Hikma Pharmaceuticals Plc Main Business 7.4.3 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.4.4 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.4.5 Hikma Pharmaceuticals Plc Recent Developments 7.5 Lupin Limited 7.5.1 Lupin Limited Profile 7.5.2 Lupin Limited Main Business 7.5.3 Lupin Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.5.4 Lupin Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.5.5 Lupin Limited Recent Developments 7.6 Mycovia Pharmaceuticals, Inc. 7.6.1 Mycovia Pharmaceuticals, Inc. Profile 7.6.2 Mycovia Pharmaceuticals, Inc. Main Business 7.6.3 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.6.4 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.6.5 Mycovia Pharmaceuticals, Inc. Recent Developments 7.7 Glenmark Pharmaceuticals Limited 7.7.1 Glenmark Pharmaceuticals Limited Profile 7.7.2 Glenmark Pharmaceuticals Limited Main Business 7.7.3 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.7.4 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.7.5 Glenmark Pharmaceuticals Limited Recent Developments 7.8 Unique Pharmaceuticals 7.8.1 Unique Pharmaceuticals Profile 7.8.2 Unique Pharmaceuticals Main Business 7.8.3 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.8.4 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.8.5 Unique Pharmaceuticals Recent Developments 7.9 PEPTONIC Medical AB 7.9.1 PEPTONIC Medical AB Profile 7.9.2 PEPTONIC Medical AB Main Business 7.9.3 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.9.4 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.9.5 PEPTONIC Medical AB Recent Developments 7.10 Aurobindo Pharma Limited 7.10.1 Aurobindo Pharma Limited Profile 7.10.2 Aurobindo Pharma Limited Main Business 7.10.3 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.10.4 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.10.5 Aurobindo Pharma Limited Recent Developments 7.11 Dr. Reddy's Laboratories 7.11.1 Dr. Reddy's Laboratories Profile 7.11.2 Dr. Reddy's Laboratories Main Business 7.11.3 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.11.4 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.11.5 Dr. Reddy's Laboratories Recent Developments 7.12 SCYNEXIS,Inc. 7.12.1 SCYNEXIS,Inc. Profile 7.12.2 SCYNEXIS,Inc. Main Business 7.12.3 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.12.4 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.12.5 SCYNEXIS,Inc. Recent Developments 7.13 Basilea Pharmaceutica Ltd. 7.13.1 Basilea Pharmaceutica Ltd. Profile 7.13.2 Basilea Pharmaceutica Ltd. Main Business 7.13.3 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.13.4 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.13.5 Basilea Pharmaceutica Ltd. Recent Developments 7.14 Astellas Pharma lnc. 7.14.1 Astellas Pharma lnc. Profile 7.14.2 Astellas Pharma lnc. Main Business 7.14.3 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.14.4 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.14.5 Astellas Pharma lnc. Recent Developments 7.15 Grupo Ferrer Internacional,S.A. 7.15.1 Grupo Ferrer Internacional,S.A. Profile 7.15.2 Grupo Ferrer Internacional,S.A. Main Business 7.15.3 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.15.4 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.15.5 Grupo Ferrer Internacional,S.A. Recent Developments 7.16 Pacgen Life Science Corporation 7.16.1 Pacgen Life Science Corporation Profile 7.16.2 Pacgen Life Science Corporation Main Business 7.16.3 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.16.4 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.16.5 Pacgen Life Science Corporation Recent Developments 7.17 NovaDigm Therapeutics, Inc. 7.17.1 NovaDigm Therapeutics, Inc. Profile 7.17.2 NovaDigm Therapeutics, Inc. Main Business 7.17.3 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.17.4 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.17.5 NovaDigm Therapeutics, Inc. Recent Developments 7.18 Cidara Therapeutics, Inc. 7.18.1 Cidara Therapeutics, Inc. Profile 7.18.2 Cidara Therapeutics, Inc. Main Business 7.18.3 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.18.4 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.18.5 Cidara Therapeutics, Inc. Recent Developments 7.19 Amplyx Pharmaceuticals Inc. 7.19.1 Amplyx Pharmaceuticals Inc. Profile 7.19.2 Amplyx Pharmaceuticals Inc. Main Business 7.19.3 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions 7.19.4 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024) 7.19.5 Amplyx Pharmaceuticals Inc. Recent Developments 8 Industry Chain Analysis 8.1 Drugs for Vaginal Fungal Infections Industrial Chain 8.2 Drugs for Vaginal Fungal Infections Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Drugs for Vaginal Fungal Infections Sales Model 8.5.2 Sales Channel 8.5.3 Drugs for Vaginal Fungal Infections Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|